Herein, the aqueous extract of Portulaca oleracea has been used as a safe, cheap, eco-friendly, and applicable scale-up method to bio-fabricate copper oxide nanoparticles (CuO-NPs). The character of CuO-NPs were determined using UV-vis spectroscopy, Fourier transform infrared (FT-IR), X-ray diffraction (XRD), Transmission electron microscopy (TEM), Energy dispersive X-ray(EDX), Dynamic light scattering (DLS), and zeta potential. Spherical and crystalline CuO-NPs with a size range of 5–30 nm at a maximum surface plasmon resonance of 275 nm were successfully fabricated. The main components of the green-synthesized particles were Cu and O with weight percentages of 49.92 and 28.45%, respectively. A Zeta-potential value of −24.6 mV was recorded for CuO-NPs, indicating their high stability. The plant-based CuO-NPs showed promising antimicrobial and catalytic activity in a dose-dependent manner. Results showed that the synthesized CuO-NPs had the efficacy to inhibit the growth of pathogens Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans with low MIC values in the ranges of 6.25–25 µg/mL. The highest decolorization percentages of tanning wastewater were attained under sunlight irradiation conditions at a concentration of 2.0 mg/mL after 200 min with percentages of 88.6 ± 1.5% compared to those which were recorded under dark conditions (70.3 ± 1.2%). The physicochemical parameters of tanning wastewater including total suspended solids (TSS), total dissolved solids (TDS), chemical oxygen demand (COD), biological oxygen demand (BOD), and conductivity under optimum conditions were significantly decreased with percentages of 95.2, 86.7, 91.4, 87.2, and 97.2%, respectively. Interestingly, the heavy metals including cobalt (Co), lead (Pb), nickel (Ni), cadmium (Cd), and chromium (Cr (VI)) decreased with percentages of 73.2, 80.8, 72.4, 64.4, and 91.4%, respectively, after treatment of tanning wastewater with CuO-NPs under optimum conditions. Overall, the plant-synthesized CuO-NPs that have antimicrobial and catalytic activities are considered a promising nano-catalyst and environmentally beneficial to wastewater treatment.

For the last few years, the world has been going through a difficult time, and the reason behind this is severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), one of the significant members of the Coronaviridae family. The major research groups have shifted their focus towards finding a vaccine and drugs against SARS-CoV-2 to reduce the infection rate and save the life of human beings. Even the WHO has permitted using certain vaccines for an emergency attempt to cut the infection curve down. However, the virus has a great sense of mutation, and the vaccine’s effectiveness remains questionable. No natural medicine is available at the community level to cure the patients for now. In this study, we have screened the vast library of experimental drugs of Drug Bank with Schrodinger’s maestro by using three algorithms: high-throughput virtual screening (HTVS), standard precision, and extra precise docking followed by Molecular Mechanics/Generalized Born Surface Area (MMGBSA). We have identified 3-(7-diaminomethyl-naphthalen-2-YL)-propionic acid ethyl ester and Thymidine-5′-thiophosphate as potent inhibitors against the SARS-CoV-2, and both drugs performed impeccably and showed stability during the 100 ns molecular dynamics simulation. Both of the drugs are among the category of small molecules and have an acceptable range of ADME properties. They can be used after their validation in in-vitro and in-vivo conditions.

With more than 17 clinically approved Drugs and over 20 prodrugs under clinical investigations, marine bacteria are believed to have a potential supply of innovative therapeutic bioactive compounds. In the current study, Kocuria sp. strain AG5 isolated from the Red Sea was identified and characterized by biochemical and physiological analysis, and examination of a phylogenetic 16S rRNA sequences. Innovative exopolysaccharide (EPS) was separated from the AG5 isolate as a major fraction of EPS (EPSR5, 6.84 g/L⁻¹). The analysis of EPSR5 revealed that EPSR5 has a molecular weight (Mw) of 4.9 × 10⁴ g/mol and number average molecular weight (Mn) of 5.4 × 10⁴ g/mol and contains sulfate (25.6%) and uronic acid (21.77%). Analysis of the monosaccharide composition indicated that the EPSR5 fraction composes of glucose, galacturonic acid, arabinose, and xylose in a molar ratio of 2.0:0.5:0.25:1.0, respectively. Assessment of the pharmacological potency of EPSR5 was explored by examining its cytotoxicity, anti-inflammatory, antioxidant, and anti-acetylcholine esterase influences. The antioxidant effect of EPSR5 was dose- and time-dependently increased and the maximum antioxidant activity (98%) was observed at 2000 µg/mL after 120 min. Further, EPSR5 displayed a significant repressive effect regarding the proliferation of HepG-2, A-549, HCT-116, MCF7, HEP2, and PC3 cells with IC₅₀ 453.46 ± 21.8 µg/mL, 873.74 ± 15.4 µg/mL, 788.2 ± 32.6 µg/mL, 1691 ± 44.2 µg/mL, 913.1 ± 38.8 µg/mL, and 876.4 ± 39.8 µg/mL, respectively. Evaluation of the inhibitory activity of the anti-inflammatory activity of EPSR5 indicated that EPSR5 has a significant inhibitory activity toward lipoxygenase (5-LOX) and cyclooxygenase (COX-2) activities (IC₅₀ 15.39 ± 0.82 µg/mL and 28.06 ± 1.1 µg/mL, respectively). Finally, ESPR5 presented a substantial hemolysis suppressive action with an IC₅₀ of 65.13 ± 0.89 µg /mL, and a considerable inhibitory activity toward acetylcholine esterase activity (IC₅₀ 797.02 μg/mL). Together, this study reveals that secondary metabolites produced by Kocuria sp. strain AG5 marine bacteria serve as an important source of pharmacologically active compounds, and their impact on human health is expected to grow with additional global work and research.

Pseudomonas aeruginosa is notorious for its ability to develop a high level of resistance to antimicrobial agents. Resistance-nodulation-division (RND) efflux pumps could mediate drug resistance in P. aeruginosa. The present study aimed to evaluate the antibacterial and anti-efflux activities of cinnamon essential oil either alone or combined with ciprofloxacin against drug resistant P. aeruginosa originated from human and animal sources. The results revealed that 73.91% of the examined samples were positive for P. aeruginosa; among them, 77.78% were of human source and 72.73% were recovered from animal samples. According to the antimicrobial resistance profile, 48.73% of the isolates were multidrug-resistant (MDR), 9.2% were extensive drug-resistant (XDR), and 0.84% were pan drug-resistant (PDR). The antimicrobial potential of cinnamon oil against eleven XDR and one PDR P. aeruginosa isolates was assessed by the agar well diffusion assay and broth microdilution technique. The results showed strong antibacterial activity of cinnamon oil against all tested P. aeruginosa isolates with inhibition zones’ diameters ranging from 34 to 50 mm. Moreover, the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values of cinnamon oil against P. aeruginosa isolates ranged from 0.0562–0.225 µg/mL and 0.1125–0.225 µg/mL, respectively. The cinnamon oil was further used to evaluate its anti-efflux activity against drug-resistant P. aeruginosa by phenotypic and genotypic assays. The cartwheel test revealed diminished efflux pump activity post cinnamon oil exposure by two-fold indicating its reasonable impact. Moreover, the real-time quantitative polymerase chain reaction (RT-qPCR) results demonstrated a significant (p < 0.05) decrease in the expression levels of MexA and MexB genes of P. aeruginosa isolates treated with cinnamon oil when compared to the non-treated ones (fold changes values ranged from 0.4204–0.7474 for MexA and 0.2793–0.4118 for MexB). In conclusion, we suggested the therapeutic use of cinnamon oil as a promising antibacterial and anti-efflux agent against drug-resistant P. aeruginosa.

Background/Objectives: Myocardial infarction (MI) and diabetes pose significant health challenges globally, necessitating the development of innovative medication strategies to improve outcomes in affected populations. This research aimed to determine the defensive impact of ferulic acid (FA) against isoproterenol-induced myocardial infarction (MI) in diabetic rats. Methods: A group of male rats was partitioned into five distinct groups: control group, diabetic group, diabetic + MI, diabetic + MI + 20 mg/kg FA, and diabetic + MI + 40 mg/kg FA. The experimental groups received isoproterenol (ISO) subcutaneously at a dosage of 50 mg/kg body weight for two consecutive days. Results: The outcome was severe cardiac toxicity, as shown by changes in electrocardiogram (ECG) rhythm and a substantial increase in blood cardiac enzymes such as creatinine kinase (CK-MB), cardiac troponin I (cTnI), and lactate dehydrogenase (LDH). Additionally, there was a surge in inflammatory cytokines, like tumor necrosis factor-alpha (TNF-α), and a disruption of the antioxidant system, evidenced by a rise in malondialdehyde (MDA) content. Moreover, there was a rise in cardiac receptor of advanced glycation end products (RAGE). Treatment with FA with escalating dosages of 20 and 40 mg/kg b.w. effectively mitigated changes in serum cardiac enzymes and improved the cellular architecture, which was evaluated by histopathological examination. Conclusions: In conclusion, in a dose-dependent manner, FA successfully showed a cardioprotective effect against ISO-induced cardiac toxicity in diabetic rats, as shown by the improvement in ECG findings, normalization of serum cardiac biomarkers, and augmentation of the endogenous antioxidant system. Therefore, the aforementioned data indicate that ferulic acid may potentially have a protective effect on MI patients who have diabetes mellitus.

Lead (Pb) is a widespread and nondegradable environmental pollutant and affects several organs through oxidative mechanisms. This study was conducted to investigate the antioxidant protective effect of glycine betaine (GB) against Pb-induced renal and hepatic injury. Male albino rats (n = 45) were divided into three groups: G1 untreated control, G2 Pb-acetate (50 mg/kg/day), and G3 Pb-acetate (50 mg/kg/day) plus GB (250 mg/kg/day) administered for 6 weeks. For G3, Pb-acetate was administered first and followed by GB at least 4 h after. Pb-acetate treatment (G2) resulted in a significant decrease in renal function, including elevated creatinine and urea levels by 17.4% and 23.7%, respectively, and nonsignificant changes in serum uric acid levels. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphates (ALP) activities were significantly increased with Pb treatment by 37.6%, 59.3%, and 55.1%, respectively. Lipid peroxidation level was significantly increased by 7.8 times after 6 weeks of Pb-acetate treatment. The level of reduced glutathione (GSH-R) significantly declined after Pb-acetate treatment. Pb-acetate treatment also reduced the activities of superoxide dismutase (SOD), glutathione-S-transferase (GST), and glutathione peroxidase (GSH-PX) by 74.1%, 85.0%, and 40.8%, respectively. Treatment of Pb-intoxicated rats with GB resulted in a significant reduction in creatinine, urea, ALT, AST, and lipid peroxidation, as well as a significant increase in the level of GSH-R and in the activities of ALP, SOD, GST, and GSH-PX. The molecular interaction between GB and GSH-PX indicated that the activation of GSH-PX in Pb-intoxicated rats was not the result of GB binding to the catalytic site of GSH-PX. The affinity of GB to bind to the catalytic site of GSH-PX is lower than that of H₂O₂. Thus, GB significantly mitigates Pb-induced renal and liver injury through the activation of antioxidant enzymes and the prevention of Pb-induced oxidative damage in the kidney and liver.